NASDAQ:RPRX
Royalty Pharma plc
Royalty Pharma plc's revenue grew 5.1% in fiscal 2025 to $2.4B while operating margin rose to 65.6%. The diluted share count fell 5.0%.Summary generated from Royalty Pharma plc's SEC filings. Latest annual report filed Feb 11, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.4B
Revenue growth+5.1%
Revenue, 5-yr CAGR+2.3%
Gross marginn/a
Operating margin65.6%
Net margin32.4%
ROIC8.9%
Return on equity7.7%
Debt / equity0.92
Free cash flown/a
FCF marginn/a
Share count change−5.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2,289 | 2,237 | 2,355 | 2,264 | 2,378 |
| Operating income | 1,431 | 307 | 1,492 | 1,292 | 1,560 |
| Net income | 620 | 43 | 1,135 | 859 | 771 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Sep 30, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KResults of a shareholder vote
Jun 4, 2026 - 8-KEntry into a material agreement
May 28, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026 - 8-KResults of operations and financial condition
May 6, 2026